Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-649266 vs Best Available Therapy for Severe Carbapenem-resistant Gram-negative Infections
2015-004703-23Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cefiderocol in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Healthcare-associated pneumonia (HCAP) and 3 more (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Clinical outcome at test of cure. Started Dec 2016; status: completed.
02
Drugs
cefiderocol
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Healthcare-associated pneumonia (HCAP)bloodstream infection (BSI)sepsis
Beyond the preview
Go deeper on 2015-004703-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004703-23.